HIPRA is researching a new vaccine for Covid-19 based on virus mRNA

Human

The pharmaceutical company HIPRA is currently working in one line of research to manufacture a new vaccine for Covid-19 in collaboration with the Hospital Clínic de Barcelona

This vaccine would be based on virus mRNA to guarantee long-term immunity. 

This line of research, which has received financial support from the CDTI and FEDER funds, began in July 2020 and ended in March 2021. 

 

Other lines of research 

Along with this line of research, the pharmaceutical company is working on another of its own thanks to its unique model that controls all phases of creating a vaccine: research, development, production and marketing. 

 

Press material
PDF
PDF